BOLD
Boundless Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.40
+0.84%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.40
From 52W high−20.00%
Volume141208.00
Market cap$55.46M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.40
From 52W high
−20.00%
Volume
141208.00
Market cap
$55.46M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
45.6
MomentumView details →
1D Return
+0.84%
YTD Return
+103.33%
SummaryUpdated Jun 1, 2026
Boundless Bio, Inc. (NASDAQ:BOLD) is a clinical-stage biotechnology company founded in 2018 and headquartered in San Diego, California. Originally incorporated as Pretzel Therapeutics, Inc., the company changed its name to Boundless Bio in July 2019 and went public in 2016. The company focuses on developing innovative cancer therapeutics specifically designed to treat patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a novel approach in oncology that addresses a previously underexplored mechanism of cancer drug resistance.
Similar companies
Latest newsMore news →
Callio Therapeutics, Inc. hired Chris Hassig as chief scientific officer.12d agoBoundless Bio, Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Serapha Bio, Inc. and Boulder Merger Sub Corp. on August 28, 2026, clarifying provisions, adding mechanics for Serapha RSU conversion and pre-funded warrant issuance, and changing the voting standard for increasing authorized shares.68d ago